Kaiser Permanente Health Plan of Mid-Atlantic States, Inc.
Sorafenib Tosylate (Nexavar) Prior Authorization (PA)
Pharmacy Benefits Prior Authorization Help Desk
Length of Authorizations: Initial- 12 months; Continuation- 12 months

Instructions:

This form is used by Kaiser Permanente and/or participating providers for coverage of **Sorafenib Tosylate (Nexavar).** Please complete and fax this form back to Kaiser Permanente within 24 hours [fax: 1-866-331-2104]. If you have any questions or concerns, please call 1-866-331-2103. **Requests will not be considered unless this form is complete. The KP-MAS Formulary can be found at: http://pithelp.appl.kp.org/MAS/formulary.html**

1 – Patient Information

Patient Name: _____ Kaiser Medical ID#: _____ Date of Birth: _____

2 – Provider Information

Prescriber specialty: □ Hematologist □ Oncologist □ other: _____

If consulted with a specialist, specialist name and specialty: _____

Provider Name: _____ Provider NPI: _____

Provider Address: _____

Provider Phone #: _____Provider Fax #: _____

Please check the boxes that apply:
□Initial Request □ Continuation of Therapy Request

3 – Pharmacy Information

Pharmacy Name: _____ Pharmacy NPI: _____

Pharmacy Phone #_____ Pharmacy Fax #: _____

4 – Drug Therapy Requested

Drug 1: Name/Strength/Formulation: _____
Sig: _____
Drug 2: Name/Strength/Formulation: _____
Sig: _____

5 – Diagnosis

Please document indication:

□ Hepatocellular carcinoma

□ Renal cell carcinoma

□ Differentiated thyroid cancer

□ Other: _____

6–Clinical Criteria

Initial Therapy:

Hepatocellular carcinoma

1. Does the member have a diagnosis of hepatocellular carcinoma and one of the following?
    a. □ No □ Yes HCC that is surgically resectable or has undergone surgical resection
    b. □ No □ Yes HCC with major vascular involvement (i.e. main portal vein, inferior vena cava, or superior mesenteric vein)
    c. □ No □ Yes HCC with tumor occupying >50% of the liver
    d. □ No □ Yes HCC with Childs-Pugh Class B or C

Renal cell carcinoma

1. Does the member have a diagnosis of metastatic renal cell carcinoma and documented treatment failure, contraindication or intolerance to two of the following regimens?
    a) □ No □ Yes Pazopanib
    b) □ No □ Yes Pembrolizumab + Axitinib
    c) □ No □ Yes Sunitinib
    d) □ No □ Yes Nivolumab + Ipilimumab
    e) □ No □ Yes Cabozantinib
    f) □ No □ Yes Lenvatinib + Everolimus
    g) □ No □ Yes Everolimus

Differentiated thyroid cancer

1. Does the member have a diagnosis of differentiated thyroid cancer and documented treatment failure, contraindication or intolerance to Lenvatinib? □ No □ Yes

Continuation of Therapy:

1. Member does NOT show evidence of progressive disease while on therapy: □ No □ Yes

7 – Provider Sign-Off

Additional Information – Please provide any additional information that should be taken into consideration.

_____

I certify that the information provided is accurate. Supporting documentation is available for State audits.

Provider Signature:	**Date:**